Souders Financial Advisors Has $1.23 Million Position in Novo Nordisk A/S (NYSE:NVO)

Souders Financial Advisors cut its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 39.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,656 shares of the company's stock after selling 11,404 shares during the period. Souders Financial Advisors' holdings in Novo Nordisk A/S were worth $1,226,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in NVO. Revolve Wealth Partners LLC grew its position in Novo Nordisk A/S by 8.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company's stock worth $214,000 after acquiring an additional 200 shares during the last quarter. Xponance Inc. grew its position in Novo Nordisk A/S by 4.9% during the 4th quarter. Xponance Inc. now owns 3,156 shares of the company's stock worth $271,000 after acquiring an additional 146 shares during the last quarter. Virtu Financial LLC grew its position in Novo Nordisk A/S by 167.5% during the 4th quarter. Virtu Financial LLC now owns 90,751 shares of the company's stock worth $7,806,000 after acquiring an additional 56,822 shares during the last quarter. Plancorp LLC grew its position in shares of Novo Nordisk A/S by 29.0% in the 4th quarter. Plancorp LLC now owns 2,534 shares of the company's stock valued at $218,000 after buying an additional 569 shares during the last quarter. Finally, Geo Capital Gestora de Recursos Ltd grew its position in shares of Novo Nordisk A/S by 157.9% in the 4th quarter. Geo Capital Gestora de Recursos Ltd now owns 71,341 shares of the company's stock valued at $6,137,000 after buying an additional 43,678 shares during the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock opened at $64.32 on Friday. Novo Nordisk A/S has a one year low of $57.00 and a one year high of $139.74. The business has a fifty day moving average price of $70.34 and a 200-day moving average price of $74.30. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.74 and a quick ratio of 0.56. The firm has a market capitalization of $287.19 billion, a P/E ratio of 19.03, a PEG ratio of 1.24 and a beta of 0.64.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.92. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. The company had revenue of $11.87 billion for the quarter. As a group, equities research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. BNP Paribas assumed coverage on Novo Nordisk A/S in a research report on Tuesday, April 15th. They set an "underperform" rating on the stock. Dbs Bank downgraded Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. BMO Capital Markets reaffirmed a "market perform" rating and issued a $64.00 target price (down from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Guggenheim lowered Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. Finally, Hsbc Global Res raised Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, April 28th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $112.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.